Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manisha Shah

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|November 25, 2020
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor CellsDwight H Owen, Brooke Benner, Carly Pilcher, et al.
Cancer|June 12, 2020
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumorsRenuka V Iyer, Bhavana Konda, Christos Fountzilas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Frontiers in Endocrinology|May 16, 2020
TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the LiteratureHinda Boutrid, Mahmoud Kassem, Gary Tozbikian, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Thyroid : Official Journal of the American Thyroid Association|March 27, 2015
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinomaSamuel A Wells, Sylvia L Asa, Henning Dralle, et al.
Thyroid : Official Journal of the American Thyroid Association|March 17, 2021
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerKeith C Bible, Electron Kebebew, James Brierley, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|November 25, 2020
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor CellsDwight H Owen, Brooke Benner, Carly Pilcher, et al.
Cancer|June 12, 2020
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumorsRenuka V Iyer, Bhavana Konda, Christos Fountzilas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Frontiers in Endocrinology|May 16, 2020
TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the LiteratureHinda Boutrid, Mahmoud Kassem, Gary Tozbikian, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Thyroid : Official Journal of the American Thyroid Association|March 27, 2015
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinomaSamuel A Wells, Sylvia L Asa, Henning Dralle, et al.
Thyroid : Official Journal of the American Thyroid Association|March 17, 2021
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerKeith C Bible, Electron Kebebew, James Brierley, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Pageof 9